New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
Fasenra (benralizumab) is a brand-name subcutaneous injection that’s prescribed for severe eosinophilic asthma in certain people. Fasenra hasn’t been reported to interact with alcohol ...
(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated vasculitis that can be ...
Some results have been hidden because they may be inaccessible to you